Daewoong Pharmaceutical’s Ursa challenges U.S. market with new look
‘Ursa’ will have a new look in 58 years of its launch. Daewoong Pharmaceutical is currently taking a new direction to renew the product which has grown 20% up in sales for the past 3 years.
With the uptrend, it is also planning to enter other advanced markets, like the U.S., beyond the No.1 Live...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.